INNATE PHARMA (EPA:IPH) Innate Pharma and Transgene Announce the Creation of Platine Pharma Services, a New Company Specialized in Immunomonitoring Services

Transparency directive : regulatory news

04/05/2011 17:50

Innate Pharma and Transgene Announce the Creation of Platine Pharma Services,
a New Company Specialized in Immunomonitoring Services

● Created on the basis of an existing collaborative platform,
  Platine Pharma Services is owned equally by Innate Pharma and Transgene.

● Platine's ambition is to become a European leader in preclinical
  and clinical immunomonitoring.

May 4, 2011 - Marseilles, Lyon and Illkirch-Graffenstaden:

Innate Pharma (Euronext Paris: FR0010331421) and Transgene (Euronext Paris:
FR0005175080) - two biotechnology companies specialized in the development of
innovative immuno therapeutics, announce the creation of Platine Pharma Services
(" Platine "). Platine is a new immunomonitoring(1) company providing fee-based
services to the healthcare industry for the preclinical and clinical development
of prophylactic and therapeutic drug candidates, notably those with immune
modulation activity such as vaccines, monoclonal antibodies or cytokines.
Platine is owned equally by Innate Pharma and Transgene.

"With Platine, Innate Pharma and Transgene combine 40 years of expertise in the
field of immunotherapeutics and measure of cellular response. As founders and
first clients, we are convinced of the relevance and added-value of Platine",
said Hervé Brailly, CEO of Innate Pharma. Philippe Archinard, Chairman and CEO
of Transgene, added: "We would like to thank all the collaborative partners as
well as the public funding bodies which contributed to the creation of Platine.
It is now up to Platine's team to continue to deliver".

Jacques Berger, previously President of Sanofi-Pasteur France, independent
Chairman of the Board of Platine Pharma Services, said: "With a broad, proven
offer, we aim at becoming a European leader in immunomonitoring. We can respond
to requests for specific as well as routine tests, from the definition of
analytical needs to data analysis. This is a high value added offer in the
context of a still fragmented European market".

(1) Immunomonitoring consists in the monitoring (cellular, molecular,
biochemical) and characterization of an immune response after a given treatment.
It is a very important step for the defining of the pharmacodynamic effect, the
mechanistic properties, the therapeutic target or the safety profile of a drug
candidate.

About Platine Pharma Services:

Platine Pharma Services offers immunomonitoring services to the healthcare
industry for the preclinical and clinical development of prophylactic and
therapeutic drug candidates, notably those with immune modulation activity such
as vaccines, monoclonal antibodies or cytokines.

Based in Lyon, in the cluster for infectious diseases, Platine offers flexible
and integrated services, from advisory to set up of immunomonitoring, routine or
"taylor made", tests. The company starts with a dozen employees and three
platforms in biochemistry, cellular and molecular biology as well as a
comprehensive panel of equipment, including flow cytometry, ELISPOT and ELISA.
For its founders and first clients, Innate Pharma and Transgene, Platine
currently runs immunomonitoring services for IPH 21, a monoclonal antibody
program developed by Innate Pharma, and for TG4040, a therapeutic vaccine
developed by Transgene.

Platine focuses on the European market, which is estimated to be in the region
of 100-200 million euros, growing at 15% per annum. The growth drivers of the
market are the increasing number of products being developed as well as the
trend towards outsourcing of this activity by biopharmaceutical players.

More information can be found at www.platine-lab.com.

For any additional information, please contact:

Samuel Salot, Chief Operating Officer       Tel : +33 (0)4 37 70 87 00
Platine Pharma Services                     Mail : samuel.salot@platine-lab.com
Bâtiment Domilyon - Centre d'infectiologie
321 avenue Jean Jaurès, 69007 Lyon Gerland

About the creation of Platine Pharma Services:

The creation of Platine originates from the will of Innate Pharma and Transgene
to pool internal resources and costs incurred for their own immunomonitoring
needs.

A collaborative program was set up in 2008 by the two partners, together with
academic laboratories (Inserm and Centre Léon-Bérard, Lyon, France) and
Grenoble-based ImmunID. This program was supported by the Lyonbiopôle cluster
and benefited from local and national public funding. A team and a platform of
services were put together during the three-year of collaborative work. Services
rendered to Innate Pharma and Transgene for their own preclinical and clinical
use enabled the building and validation of a sound expertise in the field of
immunomonitoring.

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. Its most advanced drug-candidate is IPH 2101, an anti-KIR monoclonal
antibody potentiating NK cells activation currently in Phase II clinical trials
in hematologic cancers. Two of its antibody programs in chronic inflammation are
out-licensed to Novo Nordisk A/S.

Innate Pharma's key expertise is in immunopharmacology and antibody technology.
The Company has implemented in-house a large panel of molecular and cellular
assays and in vivo models for assessing the pharmacodynamics and
pharmacotoxicology of drug candidates. In addition, Innate Pharma has access to
a very large set of unique research tools in cellular immunology through its
worldwide network of scientific collaborations.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma
is based in Marseilles, France, and had 85 employees as at March 31, 2011.

Learn more about Innate Pharma at www.innate-pharma.com.

About Transgene:

Transgene, a member of the Institut Mérieux Group, is a publicly traded French
biopharmaceutical company dedicated to the development of therapeutic vaccines
and immunotherapeutic products in oncology and infectious diseases and has five
compounds in clinical development: TG4010 and JX-594/TG6006 having completed
initial Phase II trials, TG4001 in Phase IIb trial, TG4040 in Phase II trial and
TG4023 in Phase I trial. Transgene has concluded strategic agreements for the
development of two of its immunotherapy products: an option agreement with
Novartis for the development of TG4010 to treat various cancers; and, an
in-licensing agreement with US-based Jennerex Biotherapeutics, Inc., to develop
and market JX-594/TG6006, an oncolytic product. Transgene also has
bio-manufacturing capacities for viral-based products. Additional information
about Transgene is available at www.transgene.fr.

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma and Transgene Announce the Creation of Platine Pharma Services, a New Company Specialized in Immunomonitoring Services

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories